文献速递淋巴瘤造血干细胞移植与细胞治疗

R-MegaCHOEP与R-CHOEP-14一线治疗年轻高危侵袭性B细胞淋巴瘤的10年随访:一项随机III期试验

Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
PubMed 文献 · Lancet Haematol · 2021-03-02

R-MegaCHOEP是首个对比大剂量化疗联合利妥昔单抗序贯自体造血干细胞移植与常规化疗联合利妥昔单抗一线治疗≤60岁高危侵袭性B细胞淋巴瘤的III期试验。大剂量化疗联合自体移植未改善长期生存。

要点

  • 复发患者中侵袭性组织学类型者中枢神经系统受累发生率高(28%)且预后差

核心结论

  • 大剂量化疗联合自体造血干细胞移植(R-MegaCHOEP)与常规化疗(R-CHOEP-14)相比,10年无事件生存率和总生存率均无显著差异,大剂量方案未改善长期疗效。
  • 复发时呈侵袭性组织学类型的患者中枢神经系统受累发生率高(18/64,28%)且预后差,亟需新型治疗。

研究设计与样本

  • 开放标签、随机、III期试验,在德国61个中心开展。
  • 纳入18-60岁新诊断高危(年龄调整IPI 2或3分)侵袭性B细胞淋巴瘤患者,1:1随机分配至R-CHOEP-14组(8周期常规化疗+利妥昔单抗)或R-MegaCHOEP组(4周期大剂量化疗+利妥昔单抗序贯自体HSCT)。
  • 2003年3月3日至2009年4月7日共随机275例,意向性治疗人群为R-CHOEP-14组130例、R-MegaCHOEP组132例。

主要发现

  • 190例完全缓解或未确认完全缓解患者中30例(16%,95%CI 11-22)复发,R-CHOEP-14组100例中17例(17%),R-MegaCHOEP组90例中13例(14%)。
  • 30例复发患者中7例(23%)为低级别组织学,预后优于侵袭性组织学复发者;64例治疗失败患者中18例(28%)累及中枢神经系统。

关键数值与推荐

  • 高危定义为年龄调整国际预后指数(IPI)2或3分。
  • R-CHOEP-14方案为8周期环磷酰胺、多柔比星、长春新碱、依托泊苷和泼尼松龙联合利妥昔单抗。
  • R-MegaCHOEP方案为4周期大剂量化疗联合利妥昔单抗序贯自体造血干细胞移植。

临床怎么用

  • 对于年轻高危侵袭性B细胞淋巴瘤患者,一线采用大剂量化疗联合自体造血干细胞移植(R-MegaCHOEP)未显示优于常规R-CHOEP-14的长期生存获益。
  • 复发时呈侵袭性组织学类型的患者中枢神经系统受累风险高,应关注中枢神经系统评估与预防。
  • 该类高危患者仍需探索新型治疗策略以改善预后。

局限性

  • 开放标签设计,未设盲。
  • 研究在德国单国进行,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: R-MegaCHOEP was the first phase 3 study comparing high-dose chemotherapy plus rituximab followed by autologous haematopoietic stem-cell transplantation (HSCT) with conventional chemotherapy plus rituximab in first-line therapy for patients aged 60 years or younger with high-risk aggressive B-cell lymphoma. Little is known about the long-term outcomes of these patients. We aimed to evaluate the long-term efficacy and safety of conventional chemotherapy versus high-dose chemotherapy after 10 years of follow-up in the R-MegaCHOEP trial. METHODS: In this open-label, randomised, phase 3 trial done across 61 centres in Germany, patients aged 18-60 years with newly diagnosed, high-risk (age-adjusted International Prognostic Index [IPI] 2 or 3) aggressive B-cell lymphoma were randomly assigned (1:1, using Pocock minimisation) to eight cycles of conventional chemotherapy (cyclosphosphamide, doxorubicin, vincristine, etoposide, and prednisolone) plus rituximab (R-CHOEP-14) or four cycles of high-dose chemotherapy plus rituximab followed by autologous HSCT (R-MegaCHOEP). The trial was unmasked. Patients were stratified by age-adjusted IPI factors, presence of bulky disease (tumour mass ≥7·5 cm diameter), and treatment centre. The primary endpoint was event-free survival, analysed here 10 years after randomisation. 10-year overall survival, progression-free survival, conditional survival, relapse patterns, secondary malignancies, and molecular characteristics were also analysed. All analyses were done on the intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT00129090. FINDINGS: Between March 3, 2003, and April 7, 2009, 275 patients were randomly assigned to R-CHOEP-14 (n=136) or R-MegaCHOEP (n=139). 130 patients in the R-CHOEP-14 group and 132 patients in the R-MegaCHOEP group were included in the intention-to-treat population. After a median follow-up of 9·3 years (IQR 5·1-11·1), 10-year event-free survival was 51% (95% CI 42-61) in the R-MegaCHOEP group and 57% (47-67) in the R-CHOEP-14 group (adjusted hazard ratio [HR] 1·3 [95% CI 0·9-1·8], p=0·23). 10-year progression-free survival was 59% (50-68) in the R-MegaCHOEP group and 60% (51-70) in the R-CHOEP-14 group (adjusted HR 1·1 [0·7-1·7], p=0·64). 10-year overall survival was 66% (57-76) in the R-MegaCHOEP group and 72% (63-81) in the R-CHOEP-14 group (adjusted HR 1·3 [0·8-2·1], p=0·26). Relapse occurred in 30 (16% [95% CI 11-22]) of 190 patients who had complete remission or unconfirmed complete remission; 17 (17%) of 100 patients in the R-CHOEP-14 group and 13 (14%) of 90 patients in the R-MegaCHOEP group. Seven (23%) of 30 patients had low-grade histology at relapse and had better outcomes compared with patients who relapsed with aggressive histologies. Lymphoma affected the CNS in 18 (28%) of 64 patients with treatment failure. 22 secondary malignancies were reported in the intention-to-treat population; in 12 (9%) of 127 patients in the R-CHOEP-14 group and ten (8%) of 126 patients in the R-MegaCHOEP group. INTERPRETATION: Event-free survival and overall survival were similar between groups after 10 years of follow-up; outcomes were not improved in the R-MegaCHOEP group by high-dose chemotherapy and autologous HSCT. Patients who relapsed with aggressive histology showed a high incidence of CNS involvement and poor prognosis. For these patients, novel therapies are greatly warranted. FUNDING: Deutsche Krebshilfe (German Cancer Aid).

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Frontzek F, Ziepert M, Nickelsen M, et al. Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol. 2021. PMID: 33667420. doi:10.1016/S2352-3026(21)00022-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。